Literature DB >> 25104350

Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor β (TGFβ1)-dependent paracrine mechanism.

Raghu S Nagalingam1, Nagalingam R Sundaresan2, Mariam Noor1, Mahesh P Gupta2, R John Solaro1, Madhu Gupta3.   

Abstract

Understanding the regulation of cardiac fibrosis is critical for controlling adverse cardiac remodeling during heart failure. Previously we identified miR-378 as a cardiomyocyte-abundant miRNA down-regulated in several experimental models of cardiac hypertrophy and in patients with heart failure. To understand the consequence of miR-378 down-regulation during cardiac remodeling, our current study employed a locked nucleic acid-modified antimiR to target miR-378 in vivo. Results showed development of cardiomyocyte hypertrophy and fibrosis in mouse hearts. Mechanistically, miR-378 depletion was found to induce TGFβ1 expression in mouse hearts and in cultured cardiomyocytes. Among various secreted cytokines in the conditioned-media of miR-378-depleted cardiomyocytes, only TGFβ1 levels were found to be increased. The increase was prevented by miR-378 expression. Treatment of cardiac fibroblasts with the conditioned media of miR-378-depleted myocytes activated pSMAD2/3 and induced fibrotic gene expression. This effect was counteracted by including a TGFβ1-neutralizing antibody in the conditioned-medium. In cardiomyocytes, adenoviruses expressing dominant negative N-Ras or c-Jun prevented antimiR-mediated induction of TGFβ1 mRNA, documenting the importance of Ras and AP-1 signaling in this response. Our study demonstrates that reduction of miR-378 during pathological conditions contributes to cardiac remodeling by promoting paracrine release of profibrotic cytokine, TGFβ1 from cardiomyocytes. Our data imply that the presence in cardiomyocyte of miR-378 plays a critical role in the protection of neighboring fibroblasts from activation by pro-fibrotic stimuli.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cardiac Hypertrophy; Cardiomyocyte; Fibroblast; Gene Expression; Heart Failure; MicroRNA (miRNA); Transforming Growth Factor β (TGF-B)

Mesh:

Substances:

Year:  2014        PMID: 25104350      PMCID: PMC4175354          DOI: 10.1074/jbc.M114.580977

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.

Authors:  Ning Liu; Svetlana Bezprozvannaya; Andrew H Williams; Xiaoxia Qi; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Genes Dev       Date:  2008-11-17       Impact factor: 11.361

Review 2.  MicroRNAs in control of cardiac hypertrophy.

Authors:  Paula A Da Costa Martins; Leon J De Windt
Journal:  Cardiovasc Res       Date:  2012-01-19       Impact factor: 10.787

3.  MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension.

Authors:  Giovanna Castoldi; Cira R T Di Gioia; Camila Bombardi; Daniele Catalucci; Barbara Corradi; Maria Giovanna Gualazzi; Martina Leopizzi; Massimiliano Mancini; Gianpaolo Zerbini; Gianluigi Condorelli; Andrea Stella
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

4.  Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Authors:  Rusty L Montgomery; Thomas G Hullinger; Hillary M Semus; Brent A Dickinson; Anita G Seto; Joshua M Lynch; Christianna Stack; Paul A Latimer; Eric N Olson; Eva van Rooij
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

Review 5.  Intramyocardial fibroblast myocyte communication.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

6.  miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling.

Authors:  Rudy F Duisters; Anke J Tijsen; Blanche Schroen; Joost J Leenders; Viola Lentink; Ingeborg van der Made; Veronica Herias; Rick E van Leeuwen; Mark W Schellings; Paul Barenbrug; Jos G Maessen; Stephane Heymans; Yigal M Pinto; Esther E Creemers
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

7.  Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines.

Authors:  Hongli Shan; Yong Zhang; Yanjie Lu; Ying Zhang; Zhenwei Pan; Benzhi Cai; Ning Wang; Xuelian Li; Tieming Feng; Yuan Hong; Baofeng Yang
Journal:  Cardiovasc Res       Date:  2009-04-27       Impact factor: 10.787

8.  MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.

Authors:  Scot J Matkovich; Wei Wang; Yizheng Tu; William H Eschenbacher; Lisa E Dorn; Gianluigi Condorelli; Abhinav Diwan; Jeanne M Nerbonne; Gerald W Dorn
Journal:  Circ Res       Date:  2009-11-05       Impact factor: 17.367

9.  Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice.

Authors:  Nagalingam R Sundaresan; Madhu Gupta; Gene Kim; Senthilkumar B Rajamohan; Ayman Isbatan; Mahesh P Gupta
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

10.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.

Authors:  Eva van Rooij; Lillian B Sutherland; Jeffrey E Thatcher; J Michael DiMaio; R Haris Naseem; William S Marshall; Joseph A Hill; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

View more
  19 in total

1.  Sexual dimorphism in the fetal cardiac response to maternal nutrient restriction.

Authors:  Sribalasubashini Muralimanoharan; Cun Li; Ernesto S Nakayasu; Cameron P Casey; Thomas O Metz; Peter W Nathanielsz; Alina Maloyan
Journal:  J Mol Cell Cardiol       Date:  2017-06-19       Impact factor: 5.000

Review 2.  MicroRNA: A new therapeutic strategy for cardiovascular diseases.

Authors:  Saheli Samanta; Sathyamoorthy Balasubramanian; Sheeja Rajasingh; Urmi Patel; Anuradha Dhanasekaran; Buddhadeb Dawn; Johnson Rajasingh
Journal:  Trends Cardiovasc Med       Date:  2016-03-03       Impact factor: 6.677

3.  Patients with bicuspid and tricuspid aortic valve exhibit distinct regional microrna signatures in mildly dilated ascending aorta.

Authors:  Sebastian Albinsson; Alessandro Della Corte; Azra Alajbegovic; Katarzyna K Krawczyk; Ciro Bancone; Umberto Galderisi; Marilena Cipollaro; Marisa De Feo; Amalia Forte
Journal:  Heart Vessels       Date:  2017-01-19       Impact factor: 2.037

Review 4.  Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis.

Authors:  Chunzhen Ren; Kai Liu; Xinke Zhao; Huan Guo; Yali Luo; Juan Chang; Xiang Gao; Xinfang Lv; Xiaodong Zhi; Xue Wu; Hugang Jiang; Qilin Chen; Yingdong Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 5.  TGF-β Signaling from Receptors to Smads.

Authors:  Akiko Hata; Ye-Guang Chen
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

6.  Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs.

Authors:  Scot J Matkovich; Gerald W Dorn; Tiffani C Grossenheider; Peter A Hecker
Journal:  Circ Cardiovasc Genet       Date:  2015-11-09

Review 7.  MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.

Authors:  Palak Shah; Michael R Bristow; J David Port
Journal:  Curr Heart Fail Rep       Date:  2017-12

8.  A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice.

Authors:  Ying Tian; Ying Liu; Tao Wang; Ning Zhou; Jun Kong; Li Chen; Melinda Snitow; Michael Morley; Deqiang Li; Nataliya Petrenko; Su Zhou; Minmin Lu; Erhe Gao; Walter J Koch; Kathleen M Stewart; Edward E Morrisey
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

Review 9.  MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkers.

Authors:  Fanyan Luo; Wei Liu; Haisong Bu
Journal:  Heart Fail Rev       Date:  2022-03-25       Impact factor: 4.654

10.  MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression.

Authors:  Jeongeun Hyun; Sihyung Wang; Jieun Kim; Kummara Madhusudana Rao; Soo Yong Park; Ildoo Chung; Chang-Sik Ha; Sang-Woo Kim; Yang H Yun; Youngmi Jung
Journal:  Nat Commun       Date:  2016-03-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.